Recent News

• 03.04.2025 - Genprex to Participate at BIO Europe Spring 2025
• 02.19.2025 - Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
• 02.18.2025 - Genprex Provides Update on Diabetes Gene Therapy Program
• 02.13.2025 - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
• 01.23.2025 - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
• 01.06.2025 - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
• 12.16.2024 - Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Recent Filings

• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - 8-K Current report
• 02.18.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 8-K Current report
• 01.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.23.2025 - 8-K Current report
• 01.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.13.2025 - 8-K Current report
• 01.13.2025 - EX-99.1 EX-99.1